Journal
FUTURE ONCOLOGY
Volume 17, Issue 35, Pages 4971-4982Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-0901
Keywords
advanced cutaneous squamous cell carcinoma; cemiplimab; immunotherapy; locally advanced cutaneous squamous cell carcinoma; metastatic cutaneous squamous cell carcinoma; oncholytic immunotherapy; pembrolizumab; radiation therapy; targeted therapy
Categories
Ask authors/readers for more resources
The treatment approach for advanced cutaneous squamous cell carcinoma has shifted towards immunotherapy, which has shown significant antitumor activity and durable response. The field of immunotherapeutics is continuously expanding with ongoing studies investigating adjuvant, neoadjuvant, and intralesional therapies.
Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available